NasdaqGM:ADMABiotechs
ADMA Biologics Challenges Short Report As Valuation And Compliance Scrutinized
ADMA Biologics (NasdaqGM:ADMA) issued a public response to a short-seller report from Culper Research.
The company disputed the accuracy of the allegations and reiterated its focus on regulatory compliance.
This exchange centers on claims about ADMA Biologics' business practices and disclosures.
For investors, this is notable because ADMA Biologics operates in a tightly regulated biopharmaceutical space where compliance is central to its plasma based therapies business. When a short-seller...